2017 update on Diabetic Retinopathy Preferred Practice Pattern by AAO

Published On 2017-12-22 13:32 GMT   |   Update On 2021-08-16 09:25 GMT

The American Academy of Ophthalmology (AAO) has released a 2017 update on its Preferred Practice Pattern guidelines on Diabetic Retinopathy in January 2016. The prevalence of diabetes, both worldwide and in the United States, is increasing; as such, the prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy (VTDR) is also expected to increase dramatically.Currently, only about 60% of people with diabetes have yearly screenings for diabetic retinopathy.


Major Recommendations:




  1. People with Type 1 diabetes should have annual screenings for diabetic retinopathy beginning 5 years after the onset of their disease, whereas those with Type 2 diabetes should have a prompt examination at the time of diagnosis and at least yearly examinations thereafter.

  2. Maintaining near-normal glucose levels and near-normal blood pressure lowers the risk of retinopathy developing and/or progressing, so patients should be informed of the importance of maintaining good glycosylated hemoglobin levels, serum lipids, and blood pressure.

  3. Patients with diabetes may use aspirin for other medical indications without an adverse effect on their risk of diabetic retinopathy.

  4. Women who develop gestational diabetes do not require an eye examination during pregnancy and do not appear to be at increased risk of developing diabetic retinopathy during pregnancy. However, patients with diabetes who become pregnant should be examined early in the course of the pregnancy.

  5. Referral to an ophthalmologist is required when there is any nonproliferative diabetic retinopathy, proliferative retinopathy, or macular edema.

  6. Ophthalmologists should communicate both ophthalmologic findings and level of retinopathy to the primary care physician. They should emphasize to the patient the need to adhere to the primary care physician's guidance to optimize metabolic control.

  7. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have been shown to be an effective treatment for center-involving diabetic macular edema and also as an alternative therapy for proliferative diabetic retinopathy.

  8. At this time, laser photocoagulation remains the preferred treatment for non-center-involving diabetic macular edema.


For further reference log on to :


www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2017

Tags:    
Article Source : American Academy of Ophthalmology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

NICE Guidelines on Latent TB